MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025.
Key Highlights
"As the new CEO of Accuray, I have a tremendous amount of respect for what our radiotherapy systems can do to improve cancer patients' lives for the better. While our first quarter results were soft, we were pleased to see continued expansion of our CyberKnife® and Radixact® Systems into new hospitals and markets, and we are excited about the introduction of Accuray Stellar and its potential in the U.S., where it is currently available for sale," said Steve La Neve.
Fiscal First Quarter Results
Total net revenue was $93.9 million in the first quarter of fiscal 2026, or a decrease of 7 percent, as compared to $101.5 million in the prior fiscal year first quarter. Product revenue was $37.2 million in the first quarter of fiscal 2026, or a decrease of 23 percent, as compared to $48.4 million in the prior fiscal year first quarter. Service revenue was $56.8 million in the first quarter of fiscal 2026, or an increase of 7 percent, as compared to $53.2 million in the prior fiscal year first quarter.
Total gross profit was $26.5 million in the first quarter of fiscal 2026, or 28.3 percent of total net revenue, as compared to a total gross profit of $34.5 million, or 33.9 percent of total net revenue, in the prior fiscal year first quarter. The decrease in gross margin rate was due to geographic sales mix and joint venture accounting adversely impacting product gross margins during the current quarter.
Operating expenses was $37.9 million in the first quarter of fiscal 2026, or an increase of 3 percent, as compared to $36.6 million in the prior fiscal year first quarter. The first quarter of fiscal year 2026 operating expenses included $2.4 million in restructuring charges and $0.4 million in one-time post close financing expenses. Excluding these charges, operating expenses would have decreased by 4 percent as compared to the prior fiscal year first quarter.
Net loss was $21.7 million in the first quarter of fiscal 2026, or $0.18 per share, as compared to a net loss of $4.0 million, or $0.04 per share, in the prior fiscal year first quarter. Adjusted EBITDA was a loss of $4.1 million in the first quarter of fiscal 2026, as compared to $3.1 million in the prior fiscal year first quarter.
Gross product orders was $39.6 million in the first quarter of fiscal 2026 as compared to $55.4 million in the prior fiscal year first quarter. The book to bill ratio was 1.1 in both the first quarter of fiscal 2026, and the prior fiscal year first quarter. Order backlog as of September 30, 2025 was $395.7 million, which is approximately 16 percent lower than at the end of the prior fiscal year first quarter.
Cash, cash equivalents, and short-term restricted cash were $63.9 million as of September 30, 2025, an increase of $5.9 million from June 30, 2025.
Fiscal Year 2026 Financial Guidance
The Company is reaffirming guidance for fiscal year 2026 as follows:
Guidance for non-GAAP financial measures excludes depreciation and amortization, stock-based compensation, interest expense, provision for income taxes, loss from change in fair value of warrant liability, and certain non-recurring, irregular and one-time items. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the first quarter of fiscal 2026 as well as recent corporate developments. Conference call dial-in information is as follows:
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.
In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (855) 669-9658 (USA), or (412) 317-0088 (International), Conference ID: 7403898. An archived webcast will also be available on Accuray's website until Accuray announces its results for the second quarter of fiscal 2026.
Use of Non-GAAP Financial Measures
Accuray reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP") and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA.
Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, and loss from change in fair value of warrant liability ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's guidance and future results of operations, including expectations regarding: total net revenue and adjusted EBITDA; the company's ability to deliver sustained performance and execute on its strategies, including related to its transformation efforts and restructuring plans; the company's ability to expand adjusted EBITDA margins as a percentage of revenue; the company's ability to generate increased earnings momentum; expectations regarding the impact of tariffs as well as mitigation efforts by the company; the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; expectations regarding the company's China joint venture; expectations related to the amount and timing of realizing deferred margin from the company's China joint venture; expectations with respect to strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates; expectations regarding new product introductions and innovations, including related to Accuray Stellar; expectations regarding areas of growth for the company; expectations regarding installed base growth; and the company's ability to advance patient care and offer value to its customers. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 28, 2025, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
* The Accuray Stellar System is currently available for the US market and is subject to international regulatory approval or licensing processes such that the availability of these products may vary according to geographical location.
Aman Patel, CFA | Beth Kaplan |
Investor Relations, ICR-Westwicke | Public Relations Director, Accuray |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Financial Tables to Follow
Accuray Incorporated | ||||||||
Three Months Ended | ||||||||
2025 | 2024 | |||||||
Net revenue: | ||||||||
Products | $ | 37,161 | $ | 48,369 | ||||
Services | 56,781 | 53,176 | ||||||
Total net revenue | 93,942 | 101,545 | ||||||
Cost of revenue: | ||||||||
Cost of products | 29,628 | 32,461 | ||||||
Cost of services | 37,766 | 34,615 | ||||||
Total cost of revenue | 67,394 | 67,076 | ||||||
Gross profit | 26,548 | 34,469 | ||||||
Operating expenses: | ||||||||
Research and development | 11,369 | 12,116 | ||||||
Selling and marketing | 11,973 | 11,682 | ||||||
General and administrative | 14,519 | 12,820 | ||||||
Total operating expenses | 37,861 | 36,618 | ||||||
Loss from operations | (11,313) | (2,149) | ||||||
Income (loss) from equity method investment, net | 439 | (72) | ||||||
Interest expense | (8,052) | (2,955) | ||||||
Loss from change in fair value of warrant liability | (1,874) | — | ||||||
Other (expense) income, net | (407) | 1,847 | ||||||
Loss before provision for income taxes | (21,207) | (3,329) | ||||||
Provision for income taxes | 471 | 625 | ||||||
Net loss | $ | (21,678) | $ | (3,954) | ||||
Net loss per share - basic and diluted | $ | (0.18) | $ | (0.04) | ||||
Weighted average common shares used in computing net loss per share: | ||||||||
Basic and diluted | 118,946 | 100,225 | ||||||
Accuray Incorporated | ||||||||
September 30, | June 30, | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 63,344 | $ | 57,416 | ||||
Restricted cash | 572 | 574 | ||||||
Accounts receivable, net | 54,378 | 83,192 | ||||||
Inventories, net | 155,503 | 141,020 | ||||||
Prepaid expenses and other current assets | 29,373 | 33,501 | ||||||
Deferred cost of revenue | 433 | 1,762 | ||||||
Total current assets | 303,603 | 317,465 | ||||||
Property and equipment, net | 29,013 | 28,658 | ||||||
Investment in joint venture | 4,010 | 4,612 | ||||||
Operating lease right-of-use assets, net | 32,099 | 33,115 | ||||||
Goodwill | 57,820 | 57,802 | ||||||
Long-term restricted cash | 6,012 | 4,144 | ||||||
Other assets | 24,259 | 24,443 | ||||||
Total assets | $ | 456,816 | $ | 470,239 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 42,400 | $ | 34,033 | ||||
Accrued compensation | 13,907 | 14,573 | ||||||
Operating lease liabilities, current | 7,463 | 7,375 | ||||||
Other accrued liabilities | 26,271 | 29,361 | ||||||
Customer advances | 12,087 | 12,197 | ||||||
Deferred revenue | 79,631 | 82,306 | ||||||
Short-term debt | 12,853 | 12,734 | ||||||
Total current liabilities | 194,612 | 192,579 | ||||||
Operating lease liabilities, non-current | 31,481 | 32,482 | ||||||
Long-term other liabilities | 5,345 | 5,160 | ||||||
Warrant liability | 10,371 | 8,497 | ||||||
Deferred revenue, non-current | 25,824 | 26,566 | ||||||
Long-term debt | 127,316 | 123,786 | ||||||
Total liabilities | 394,949 | 389,070 | ||||||
Stockholders' equity: | ||||||||
Common stock | 113 | 113 | ||||||
Additional paid-in capital | 604,680 | 602,165 | ||||||
Accumulated other comprehensive loss | (1,976) | (1,837) | ||||||
Accumulated deficit | (540,950) | (519,272) | ||||||
Total stockholders' equity | 61,867 | 81,169 | ||||||
Total liabilities and stockholders' equity | $ | 456,816 | $ | 470,239 | ||||
Accuray Incorporated | ||||||||
Three Months Ended | ||||||||
2025 | 2024 | |||||||
Gross orders | $ | 39,570 | $ | 55,365 | ||||
Net orders | 5,916 | 29,656 | ||||||
Order backlog | 395,726 | 468,607 | ||||||
Book to bill ratio (a) | 1.1 | 1.1 | ||||||
(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period. |
Accuray Incorporated | ||||||||
Three Months Ended | ||||||||
2025 | 2024 | |||||||
GAAP net loss | $ | (21,678) | $ | (3,954) | ||||
Depreciation and amortization (a) | 1,676 | 1,464 | ||||||
Stock-based compensation | 2,515 | 2,354 | ||||||
Interest expense, net (b) | 7,780 | 2,652 | ||||||
Provision for income taxes | 471 | 625 | ||||||
Loss from change in fair value of warrant liability | 1,874 | — | ||||||
Restructuring charges | 2,811 | — | ||||||
Post-financing costs | 441 | — | ||||||
Adjusted EBITDA | $ | (4,110) | $ | 3,141 | ||||
(a) Consists of depreciation on property and equipment and amortization of intangibles. |
(b) Consists of interest expense net of interest income. |
Accuray Incorporated | ||||||||
Twelve Months Ending | ||||||||
From | To | |||||||
GAAP net loss | $ | (30,000) | $ | (27,500) | ||||
Depreciation and amortization (a) | 8,500 | 8,500 | ||||||
Stock-based compensation | 11,000 | 11,000 | ||||||
Interest expense, net (b) | 30,000 | 30,000 | ||||||
Provision for income taxes | 3,000 | 3,000 | ||||||
Loss from change in fair value of warrant liability | 2,000 | 2,000 | ||||||
Restructuring charges | 5,000 | 6,000 | ||||||
Post-financing costs | 1,500 | 2,000 | ||||||
Adjusted EBITDA | $ | 31,000 | $ | 35,000 | ||||
(a) Consists of depreciation on property and equipment and amortization of intangibles. |
(b) Consists of interest expense net of interest income. |
| Last Trade: | US$0.98 |
| Daily Change: | -0.02 -1.94 |
| Daily Volume: | 10,134,853 |
| Market Cap: | US$110.620M |
October 20, 2025 October 08, 2025 September 30, 2025 September 26, 2025 September 11, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
